Form 8-K - Current report:
SEC Accession No. 0001193125-25-008477
Filing Date
2025-01-17
Accepted
2025-01-17 17:00:31
Documents
13
Period of Report
2025-01-13
Items
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

Document Format Files

Seq Description Document Type Size
1 8-K d927403d8k.htm   iXBRL 8-K 25738
  Complete submission text file 0001193125-25-008477.txt   152985

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA omga-20250113.xsd EX-101.SCH 2868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE omga-20250113_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE omga-20250113_pre.xml EX-101.PRE 11719
15 EXTRACTED XBRL INSTANCE DOCUMENT d927403d8k_htm.xml XML 3767
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 25539427
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)